Nkarta Therapeutics is a leading brand in the field of cell therapy, focused on developing the next generation of cell therapies using their proprietary Natural Killer (NK) cell expansion technology. Unlike T-cell therapy, which has limitations in its application, NK cells have an inherent ability to target and destroy tumor cells without genetic alteration. This makes them a promising candidate for the development of potent therapies for various tumor types.

Nkarta's innovative approach enhances the power of NK cells to boost their ability to eliminate tumor cells while offering a better tolerated safety profile. Their mission is to improve the efficacy of cell therapy, making it more potent and rapidly available to a broad population of patients with hematologic and solid tumor malignancies. Under the leadership of President and CEO Paul Hastings, and a team of experienced professionals in the field of cell therapy, Nkarta is at the forefront of advancing this groundbreaking technology.

With a focus on technical operations, manufacturing, quality, legal affairs, finance, and clinical development, the company is dedicated to bringing effective and safe cell therapies to patients in need